Market Research Logo

Prescription Drugs Market Research Reports & Industry Analysis

In April 2011, the Food and Drug Administration (FDA) announced a new program focused on curbing the abuse and reducing associated risks of prescription opioid painkillers. The Risk Evaluation and Mitigation Strategy (REMS) program focuses primarily on educating doctors about proper pain management, patient selection and improving patient awareness about how to use these drugs safely.

According to the White House, prescription drug abuse has become an epidemic, estimating that in 2007 alone, over 33 million Americans age 12 and older misused opioid painkillers. That same year, drug overdose in the U.S. was one of the leading causes of unintentional injury death, second only to motor vehicle accidents.

One important target of the campaign is the safe disposal of medications. In many cases, doctors have been found to prescribe larger doses of opioids than patients actually use. Many of these pills find their way onto the black market. Additionally, more than half of all non-prescribed painkiller users get their drugs from someone they know. As part of the plan, FDA wants opioid manufacturers to provide prescribing physicians with educational materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

The drugs targeted by the REMS plan include brand name products known under the generic names hydromorphone, oxycodone, morphine, oxymorphone, methadone, transdermal fentanyl, and transdermal buprenorphine.

...Show More ...Show Less


Prescription Drugs Industry Research & Market Reports

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2018

    ... within the generic medicines sector, while the larger, moredeveloped markets present viable opportunities for patented medicine sales in urban regions. Cooperative agreements withinternational firms will provide opportunities for domestic firms to expand their manufacturing capacities. Read More

  • Middle East And North Africa Pharmaceuticals & Healthcare Q4 2018

    ... opportunities for multinational drugmakers looking to expand to emergingmarkets. Heightened industry and country risk dissuade company interest and the larger markets dominate multinational activityfor patented medicine sales. Ample opportunities exist in the generics market segment. Read More

  • Costa Rica Pharmaceuticals & Healthcare Q4 2018

    ... offers superior market access and development opportunities to multinationals based on factorssuch as continuous improvement in healthcare infrastructure and government commitment to upholding an attractive businessenvironment. Additionally, the demand for innovative medicines will still need ... Read More

  • Europe Pharmaceuticals & Healthcare Q4 2018

    ... to region-specific trends. Themore developed Western markets will continue to be favoured by innovative drugmakers due to stronger regulatory oversight andgreater purchasing power, although growth in these markets will be suppressed by aggressive cost-containment. Revenue ... Read More

  • Ghana Pharmaceuticals & Healthcare Q4 2018

    ... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More

  • Hong Kong Pharmaceuticals & Healthcare Q4 2018

    ... cope with a rapidly ageing population. On the private side too, the government has beenpromoting the development of private hospitals as part of its reform initiatives to improve the long-term sustainability of thecountry’s healthcare system. Read More

  • Asia Pharmaceuticals & Healthcare Q4 2018

    ... However, these markets will no longer providesignificant revenue growth due to aggressive cost-containment. Instead, growth opportunities will be plentiful in emerging markets.We note that due to continued regulatory challenges and a growing focus on cost-efficiency, ... Read More

  • El Salvador Pharmaceuticals & Healthcare Q4 2018

    ... for pharmaceutical investment. Despite this, a steady number ofcollaborations with international organisations and businesses is improving the standard of healthcare and raising the long-termgrowth prospects of the country's low penetration of pharmaceuticals and medical equipment. Read More

  • Germany Pharmaceuticals & Healthcare Q4 2018

    ... to services, will continue tosupport this potential. However, we do caution that market access is now challenging, as authorities use a range of cost-containment measures and downward price pressures as a means of controlling state ... Read More

  • Nicaragua Pharmaceuticals & Healthcare Q4 2018

    ... pharmaceutical companies operating in thecountry. Furthermore, the ongoing political crisis and heightened social unrest will exacerbate the risks associated with Nicaragua,further deterring multinational drugmakers from investing in what is already one of the least attractive ... Read More

  • Uganda Pharmaceuticals & Healthcare Q4 2018

    ... remain dominant, while the government plans to localisedrug production to boost medicine sustainability. While the market has brighter long-term prospects, multinational drugmakerappetite will remain subdued despite the positive economic growth forecast over the coming years. Read More

  • Global Bipolar Disorder Therapeutic Market 2019-2023

    ... hypomania, which differs based on the severity and presence of psychosis. Bipolar disorder is a long-lasting condition that can be categorized into bipolar I, bipolar II, and cyclothymia. This condition can be managed with a ... Read More

  • Pharmaceuticals in Australia

    ... national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market ... Read More

  • Azerbaijan Pharmaceuticals & Healthcare Q4 2018

    ... pharmaceutical market, we remain cautious about its commercial attractiveness to multinationals, at least in theshort term. The over-reliance on out-of-pocket payments has made the market vulnerable to economic fluctuations, especiallygiven its reliance on imported medicines. Read More

  • Namibia Pharmaceuticals & Healthcare Q4 2018

    ... and efficiency issues within the public healthcare sector. The small middle-and upper-class segments provide pockets of demand for innovative medicines, which will continue to be imported by key regionalplayers and representative offices of established multinationals. Read More

  • Panama Pharmaceuticals & Healthcare Q4 2018

    ... system inefficiencies will continueto weigh on the country’s ability to improve access to healthcare. Sustained pro-growth economic policies and the Panama Canalwill continue to support the country’s position as a logistic and export hub, including ... Read More

  • Honduras Pharmaceuticals & Healthcare Q4 2018

    ... in Central America. The limited demand forpatented medicines is highlighted by the country’s low per capita spending on medicines. However, a growing burden of chronicdiseases driven by ageing demographics in addition to planned healthcare reforms ... Read More

  • Pakistan Pharmaceuticals & Healthcare Q4 2018

    ... especially in light of the uncertainpolicy directions. In addition, the Pakistan-Tehreek-e-Insaf (PTI) political party is expected to upscale health coverage, increase thenumber of emergency units and generally implement programmes to improve health outcomes. Furthermore, the ... Read More

  • Slovakia Pharmaceuticals & Healthcare Q4 2018

    ... be driven bygovernment plans to improving access to health services with hospital reforms and diseases prevention programs. However, thegovernment’s implementation of cost-containment measures and the growing use of generic medicines will limit opportunities forinnovative drugmakers. Read More

  • Myanmar Pharmaceuticals & Healthcare Q4 2018

    ... underdeveloped state of the public health sector will shape commercialopportunities for private healthcare providers. Despite this, the upcoming rollout of universal healthcare coverage will improve long-term opportunities for investment in Myanmar’s pharmaceutical and healthcare sectors. Read More

  • Tunisia Pharmaceuticals & Healthcare Q4 2018

    ... will challenge foreign investment into the sector.Highlighting the market's longer-term potential, some multinational drugmakers have shown their willingness to do business in thecountry, though the majority choose to operate indirectly to minimise the risks involved. Read More

  • Austria Pharmaceuticals & Healthcare Q4 2018

    ... sizecompared to its EU partners. However, like its eurozone neighbours, we believe Austria's pharmaceutical spending will be subduedover the medium term, as states scramble to contain rising pharmaceutical expenditure in line with increasing healthcare demands. Read More

  • Gabon Pharmaceuticals & Healthcare Q4 2018

    ... by factors including modest but growingpopulation numbers, high prevalence of infectious diseases and the growing burden of civilisation diseases. However, given thetight funding environment, most of the commercial opportunities remain limited to the generics sector. Read More

  • Armenia Pharmaceuticals & Healthcare Q4 2018

    ... the previous administration's courseand, as such, publicly funded access to healthcare services will remain lacking. Longer-term prospects remain dependent on thewider economic situation, especially as private out-of-pocket spending remains the dominant source of healthcare funding. Read More

  • Portugal Pharmaceuticals & Healthcare Q4 2018

    ... increasingly important role in the healthcaresystem. Despite rising public health spending, the public hospital sector will continue to face challenges after several years ofdeterioration and management concerns. Although commercial opportunities for drugmakers will significantly improve ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog